CD274 and non-small cell lung carcinoma: The advent of immune checkpoint inhibitors (ICIs) targeting programmed death 1 (PD-1)/PD-L1 axis has transformed therapeutic paradigms, with agents like atezolizumab achieving first-line approval for advanced NSCLC (6).